ID

42567

Descripción

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00824668

Link

https://clinicaltrials.gov/show/NCT00824668

Palabras clave

Versiones (2)
  1. 10/3/18 10/3/18 -
  2. 2/9/21 2/9/21 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

2 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes NCT00824668

Inglés

Eligibility Diabetes NCT00824668

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00824668
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes mellitus for 12 months or longer
Descripción

Non-Insulin-Dependent Diabetes Mellitus Disease length

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
body mass index (bmi): 25.0-40.0 kg/m2, both inclusive
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
hba1c between 7.0 and 10.5% at screening
Descripción

Glucohemoglobin measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0202054
insulin treatment for at least 3 months prior to screening with a total daily dose of 0.6 and 0.9 u/kg body weight
Descripción

Insulin regime U/day

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0557978
UMLS CUI [1,2]
C0456683
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of any oral antidiabetic agent within the past 2 months
Descripción

Antidiabetics Oral

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1527415
cardiac disease: nyha class iii or iv chronic heart failure (chf), unstable angina, and/or any myocardial infarction (treated or untreated) within 6 months prior to screening
Descripción

Heart Diseases | Chronic heart failure New York Heart Association Classification | Angina, Unstable | Myocardial Infarction Treated | Myocardial Infarction untreated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2,1]
C0264716
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0002965
UMLS CUI [4,1]
C0027051
UMLS CUI [4,2]
C1522326
UMLS CUI [5,1]
C0027051
UMLS CUI [5,2]
C0332155
hepatic insufficiency (alanine aminotransferase (alt) or aspartate aminotransferase (ast) equal to or greater than 2 times the central laboratory's upper reference limit)
Descripción

Hepatic Insufficiency | Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1306571
UMLS CUI [2]
C0151905
UMLS CUI [3]
C0151904
renal insufficiency (serum creatinine equal to or greater than 1.6 mg/dl for males; equal to or greater than 1.4 mg/dl for females)
Descripción

Renal Insufficiency | Creatinine measurement, serum | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
UMLS CUI [3]
C0079399
recurrent hypoglycaemia
Descripción

Recurrent hypoglycemia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1846288
anaemia (haemoglobin less than 13.0 mg/dl in males and less than 12.0 mg/dl in females; who-criteria)
Descripción

Anemia | Hemoglobin measurement | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0002871
UMLS CUI [2]
C0518015
UMLS CUI [3]
C0079399
use of concomitant medications (prescribed or non-prescribed and other than insulin) which may alter glucose metabolism including but not limited to: systemic or inhaled glucocorticoids, anabolic steroids, non-selective beta-blockers
Descripción

Pharmaceutical Preparations Changing Glucose metabolism | Non-Prescription Drugs Changing Glucose metabolism | Exception Insulin | Glucocorticoids, Systemic | Glucocorticoids Inhalation | Anabolic steroids | Non-selective beta-blocking agent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392747
UMLS CUI [1,3]
C0596620
UMLS CUI [2,1]
C0013231
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C0596620
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0021641
UMLS CUI [4]
C3540777
UMLS CUI [5,1]
C0017710
UMLS CUI [5,2]
C0205535
UMLS CUI [6]
C0002845
UMLS CUI [7]
C0304515
Volver a la parte superior de la página

Similar models

Eligibility Diabetes NCT00824668

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT00824668
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
type 2 diabetes mellitus for 12 months or longer
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Body mass index
Item
body mass index (bmi): 25.0-40.0 kg/m2, both inclusive
boolean
C1305855 (UMLS CUI [1])
Glucohemoglobin measurement
Item
hba1c between 7.0 and 10.5% at screening
boolean
C0202054 (UMLS CUI [1])
Insulin regime U/day
Item
insulin treatment for at least 3 months prior to screening with a total daily dose of 0.6 and 0.9 u/kg body weight
boolean
C0557978 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Antidiabetics Oral
Item
use of any oral antidiabetic agent within the past 2 months
boolean
C0935929 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
Heart Diseases | Chronic heart failure New York Heart Association Classification | Angina, Unstable | Myocardial Infarction Treated | Myocardial Infarction untreated
Item
cardiac disease: nyha class iii or iv chronic heart failure (chf), unstable angina, and/or any myocardial infarction (treated or untreated) within 6 months prior to screening
boolean
C0018799 (UMLS CUI [1])
C0264716 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0002965 (UMLS CUI [3])
C0027051 (UMLS CUI [4,1])
C1522326 (UMLS CUI [4,2])
C0027051 (UMLS CUI [5,1])
C0332155 (UMLS CUI [5,2])
Hepatic Insufficiency | Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
hepatic insufficiency (alanine aminotransferase (alt) or aspartate aminotransferase (ast) equal to or greater than 2 times the central laboratory's upper reference limit)
boolean
C1306571 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
Renal Insufficiency | Creatinine measurement, serum | Gender
Item
renal insufficiency (serum creatinine equal to or greater than 1.6 mg/dl for males; equal to or greater than 1.4 mg/dl for females)
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Recurrent hypoglycemia
Item
recurrent hypoglycaemia
boolean
C1846288 (UMLS CUI [1])
Anemia | Hemoglobin measurement | Gender
Item
anaemia (haemoglobin less than 13.0 mg/dl in males and less than 12.0 mg/dl in females; who-criteria)
boolean
C0002871 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Pharmaceutical Preparations Changing Glucose metabolism | Non-Prescription Drugs Changing Glucose metabolism | Exception Insulin | Glucocorticoids, Systemic | Glucocorticoids Inhalation | Anabolic steroids | Non-selective beta-blocking agent
Item
use of concomitant medications (prescribed or non-prescribed and other than insulin) which may alter glucose metabolism including but not limited to: systemic or inhaled glucocorticoids, anabolic steroids, non-selective beta-blockers
boolean
C0013227 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
C0596620 (UMLS CUI [1,3])
C0013231 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0596620 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0021641 (UMLS CUI [3,2])
C3540777 (UMLS CUI [4])
C0017710 (UMLS CUI [5,1])
C0205535 (UMLS CUI [5,2])
C0002845 (UMLS CUI [6])
C0304515 (UMLS CUI [7])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial